Bethany Kaplan

Preclinical Response of Uveal Melanomas to the Velcrin Compound, BAY 2666605

Kristýna Kotýnková, Sawyer Andersen, D.R. Denney, Gizem Karsli Uzunbas et autres

Velcrin compounds kill cancer cells expressing elevated levels of two cellular proteins, the PDE3A phosphodiesterase and the SLFN12 tRNase, by inducing PDE3A-SLFN12 complex formation. This results in activation of SLFN12, leading to digestion of its specific substrate, tRNA-Leu-TAA, inhibition of protein synthesis, …

us, ch (code pays fourni par la source)

Abstract 1939: Oncogenic NSD2 drives Eph-ephrin signaling between myeloma and bone marrow stromal cells.

Austin C. Boese, Lindsey Rosas Togo, Qing Wu, Bethany Kaplan et autres

Abstract The t(4;14) translocation occurs in 15-20% of multiple myeloma cases and upregulates the histone methyltransferase NSD2 to drive oncogenic transcriptional dysregulation. Patients with t(4;14)+ myeloma are high risk with shorter survival and higher incidence of bone lesions when compared to patients …

us (code pays fourni par la source)

Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 point mutations

Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Abstract Exon 20 insertions of HER2, encoded by erb-b2 receptor tyrosine kinase 2 (ERBB2), and other activating HER2 mutations occur in 2% to 4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. Sevabertinib (BAY 2927088) is …

Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Biochemical kinase activity of sevabertinib in ERBB and non-ERBB family kinases

Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Crystallographic data collection and refinement statistics for the co-crystal structure of wild-type EGFR with sevabertinib

Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Sevabertinib inhibition in KinaseProfiler kinase activity platform

Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 Exon 20 insertion mutations

Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Additional cell viability data of zongertinib and STX-721 in isogenic Ba/F3 cell lines

Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Antitumor efficacy of sevabertinib in the subcutaneous CTG-2543 xenografts

Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models

Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas et autres

NRG1 fusions in cancer cell lines